Essential thrombocytosis cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{{CMG}} | {{CMG}} | ||
Please help WikiDoc by adding content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | |||
==References== | ==References== |
Latest revision as of 13:44, 16 November 2015
Essential thrombocytosis Microchapters |
Differentiating Essential thrombocytosis from other Diseases |
---|
Diagnosis |
Treatment |
Essential thrombocytosis cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Essential thrombocytosis cost-effectiveness of therapy |
FDA on Essential thrombocytosis cost-effectiveness of therapy |
CDC on Essential thrombocytosis cost-effectiveness of therapy |
Essential thrombocytosis cost-effectiveness of therapy in the news |
Blogs on Essential thrombocytosis cost-effectiveness of therapy |
Risk calculators and risk factors for Essential thrombocytosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.